MANTLE CELL LYMPHOMA

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy for people newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see if this approach can shrink tumors and reduce canc…

This study tests whether giving a targeted drug (ibrutinib) plus an immunotherapy (rituximab) before standard chemotherapy can improve outcomes for young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. About 131 participants will receive the combin…

This study tests a combination of two drugs, acalabrutinib and rituximab, in elderly patients (65 and older) with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see how well the treatment controls the cancer and what side effects occur. About 53 participan…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests whether adding a stem cell transplant to maintenance therapy with rituximab helps people with mantle cell lymphoma stay in remission longer compared to rituximab alone. About 689 adults aged 18-70 whose cancer is in first complete remission with no detectable dis…

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This study tested a two-step drug combination for people with untreated mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. The goal was to see if the combination could improve the number of patients who achieve complete remission before a s…

This study tests a combination of three drugs (acalabrutinib, lenalidomide, and either rituximab or obinutuzumab) in people with untreated mantle cell lymphoma, a rare blood cancer. About 37 participants will receive the treatment for about a year, then continue on a lower mainte…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This study tests a new drug, MK-2140, alone or with other treatments, in people with certain B-cell blood cancers that have come back or not responded to prior therapy. About 223 adults with mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or Richter trans…

This study tests the drug ibrutinib in 20 people with a slow-growing form of mantle cell lymphoma that hasn't been treated yet. The goal is to see if ibrutinib can stop or slow the cancer from getting worse. Participants take the drug and are monitored for side effects and how lo…

This study tests a new drug called BGB-11417 (sonrotoclax) for people with mantle cell lymphoma that has returned or stopped responding to other treatments. The drug works by blocking a protein that helps cancer cells survive. The trial has two parts: first, finding the safest do…

This study tests a drug called acalabrutinib in people with mantle cell lymphoma who couldn't handle the side effects of ibrutinib. The goal is to see if acalabrutinib can shrink or control the cancer without causing the same problems. About 9 participants will take the drug and …

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study tests a new stem cell treatment called MGTA-456 for people with high-risk blood cancers like leukemia and lymphoma. The treatment uses a special process to grow more stem cells from donated umbilical cord blood before transplant. The goal is to help the body rebuild he…

This early-phase study tests whether giving two drugs (acalabrutinib and rituximab) followed by a special immune cell treatment (brexucabtagene autoleucel, a type of CAR T-cell therapy) can help control high-risk mantle cell lymphoma that hasn't been treated before. About 22 peop…

This early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in adults with mantle cell lymphoma that has come back or not responded to prior treatment. The main goal is to find the safest dose by monitoring side effects. Up to 27 participant…

This study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to see how well the drugs work together to shrink or control the cancer. Abou…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study tests a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see how many patients achieve a complete response (no cancer detected) after treatment. About 50 adults wil…

This early-phase study tests whether combining glofitamab and lenalidomide can help people with mantle cell lymphoma that has returned or not responded to previous treatments, including a BTK inhibitor. About 39 adults will take part. The main goal is to see if the treatment plan…

This study tests whether adding venetoclax to a standard treatment (ibrutinib plus a CD20 antibody) works better for people newly diagnosed with mantle cell lymphoma, a rare blood cancer. About 194 adults aged 18 to 79 will receive either the standard combo or the three-drug comb…

This study tests three different chemotherapy combinations in adults aged 70 or younger with newly diagnosed mantle cell lymphoma, a rare and aggressive blood cancer. The goal is to see which combination works best to shrink tumors and clear cancer cells from the blood. Participa…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests a mix of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 young adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see how well the combination shrinks tumors and controls the disease. Participants recei…

This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…

This study tests a combination of two drugs, ibrutinib and rituximab, in 50 adults with a slow-growing form of mantle cell lymphoma who have not had prior treatment. The main goal is to see how many patients achieve complete remission one year after starting therapy. Researchers …

This study examines stored tissue samples from 160 people with mantle cell lymphoma whose cancer came back or didn't respond to initial chemotherapy and rituximab. Researchers will analyze the samples to identify genetic and cellular features linked to treatment resistance. The g…